Amneal Pharmaceuticals, Inc. Stock

Equities

AMRX

US03168L1052

Pharmaceuticals

Market Closed - Nasdaq 16:00:00 2024-06-12 EDT 5-day change 1st Jan Change
7.11 USD +1.14% Intraday chart for Amneal Pharmaceuticals, Inc. +4.41% +17.13%
Sales 2024 * 2.67B 3.66B Sales 2025 * 2.79B 3.83B Capitalization 2.19B 3.01B
Net income 2024 * -84M -115M Net income 2025 * 23M 31.6M EV / Sales 2024 * 1.7 x
Net Debt 2024 * 2.35B 3.23B Net Debt 2025 * 2.12B 2.92B EV / Sales 2025 * 1.55 x
P/E ratio 2024 *
-26.3 x
P/E ratio 2025 *
102 x
Employees 7,850
Yield 2024 *
0.42%
Yield 2025 *
-
Free-Float 26.13%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.14%
1 week+4.41%
Current month+6.44%
1 month+6.76%
3 months+33.90%
6 months+53.23%
Current year+17.13%
More quotes
1 week
6.64
Extreme 6.64
7.25
1 month
6.42
Extreme 6.42
7.25
Current year
5.01
Extreme 5.01
7.25
1 year
2.29
Extreme 2.29
7.25
3 years
1.24
Extreme 1.24
7.25
5 years
1.24
Extreme 1.24
7.48
10 years
1.24
Extreme 1.24
24.48
More quotes
Managers TitleAgeSince
Founder 57 01-12-31
Founder 53 01-12-31
Director of Finance/CFO 57 11-06
Members of the board TitleAgeSince
Director/Board Member 66 11-06
Director/Board Member 69 11-06
Chairman 71 11-06
More insiders
Date Price Change Volume
24-06-12 7.11 +1.14% 1,408,196
24-06-11 7.03 +2.63% 2,694,657
24-06-10 6.85 +1.48% 1,789,844
24-06-07 6.75 +0.90% 1,084,656
24-06-06 6.69 -1.76% 1,192,052

Delayed Quote Nasdaq, June 12, 2024 at 04:00 pm

More quotes
Amneal Pharmaceuticals, Inc., is a fully integrated global essential medicine company. The Company is engaged in the development, manufacturing, and distribution of a diverse portfolio of approximately 270 pharmaceutical products, primarily within the United States. The Company’s Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermal across a broad range of therapeutic categories. The Company's Specialty segment’s portfolio includes central nervous system disorders (Parkinson’s disease, spasticity, migraine), endocrinology (hypothyroidism), and other therapeutic areas. The Company’s AvKARE segment provides pharmaceuticals, medical and surgical products, and services to government, retail, and institutional markets.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
7.11 USD
Average target price
8.25 USD
Spread / Average Target
+16.03%
Consensus